• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病患者认知轨迹相关的神经心理学和临床变量

Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease.

作者信息

Riello Marianna, Moroni Monica, Bovo Stefano, Ragni Flavio, Buganza Manuela, Di Giacopo Raffaella, Chierici Marco, Gios Lorenzo, Pardini Matteo, Massa Federico, Dallabona Monica, Vanzetta Elisa, Campi Cristina, Piana Michele, Garbarino Sara, Marenco Manuela, Osmani Venet, Jurman Giuseppe, Uccelli Antonio, Giometto Bruno

机构信息

Neurology Unit, Provincial Health Services of Trento, Trento, Italy.

Data Science for Health Unit, Fondazione Bruno Kessler, Trento, Italy.

出版信息

Front Aging Neurosci. 2025 May 27;17:1565006. doi: 10.3389/fnagi.2025.1565006. eCollection 2025.

DOI:10.3389/fnagi.2025.1565006
PMID:40496971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12149119/
Abstract

BACKGROUND

The NeuroArtP3 (NET-2018-12366666) is a multicenter study funded by the Italian Ministry of Health. The aim of the project is to identify the prognostic trajectories of Alzheimer's disease (AD) through the application of artificial intelligence (AI). Only a few AI studies investigated the clinical variables associated with cognitive worsening in AD. We used Mini Mental State Examination (MMSE) scores as outcome to identify the factors associated with cognitive decline at follow up.

METHODS

A sample of = 126 patients diagnosed with AD (MMSE >19) were followed during 3 years in 4 time-points: T0 for the baseline and T1, T2 and T3 for the years of follow-ups. Variables of interest included demographics: age, gender, education, occupation; measures of functional ability: Activities of Daily Living (ADLs) and Instrumental (IADLs); clinical variables: presence or absence of comorbidity with other pathologies, severity of dementia (Clinical Dementia Rating Scale), behavioral symptoms; and the equivalent scores (ES) of cognitive tests. Logistic regression, random forest and gradient boosting were applied on the baseline data to estimate the MMSE scores (decline of at least >3 points) measured at T3. Patients were divided into multiple splits using different model derivation (training) and validation (test) proportions, and the optimization of the models was carried out through cross validation on the derivation subset only. The models predictive capabilities (balanced accuracy, AUC, AUPCR, F1 score and MCC) were computed on the validation set only. To ensure the robustness of the results, the optimization was repeated 10 times. A SHAP-type analysis was carried out to identify the predictive power of individual variables.

RESULTS

The model predicted MMSE outcome at T3 with a mean AUC of 0.643. Model interpretability analysis revealed that the global cognitive state progression in AD patients is associated with: low spatial memory (Corsi block-tapping), verbal episodic long-term memory (Babcock's story recall) and working memory (Stroop Color) performances, the presence of hypertension, the absence of hypercholesterolemia, and functional skills inabilities at the IADL scores at baseline.

CONCLUSION

This is the first AI study to predict cognitive trajectories of AD patients using routinely collected clinical data, while at the same time providing explainability of factors contributing to these trajectories. Also, our study used the results of single cognitive tests as a measure of specific cognitive functions allowing for a finer-grained analysis of risk factors with respect to the other studies that have principally used aggregated scores obtained by short neuropsychological batteries. The outcomes of this work can aid prognostic interpretation of the clinical and cognitive variables associated with the initial phase of the disease towards personalized therapies.

摘要

背景

NeuroArtP3(NET - 2018 - 12366666)是一项由意大利卫生部资助的多中心研究。该项目的目的是通过应用人工智能(AI)来确定阿尔茨海默病(AD)的预后轨迹。只有少数AI研究调查了与AD认知恶化相关的临床变量。我们使用简易精神状态检查表(MMSE)评分作为结果,以确定随访时与认知衰退相关的因素。

方法

对126例被诊断为AD(MMSE>19)的患者样本进行了3年的随访,共4个时间点:T0为基线,T1、T2和T3为随访年份。感兴趣的变量包括人口统计学特征:年龄、性别、教育程度、职业;功能能力指标:日常生活活动(ADL)和工具性日常生活活动(IADL);临床变量:是否合并其他疾病、痴呆严重程度(临床痴呆评定量表)、行为症状;以及认知测试的等效分数(ES)。对基线数据应用逻辑回归、随机森林和梯度提升算法,以估计在T3时测得的MMSE评分(至少下降>3分)。使用不同的模型推导(训练)和验证(测试)比例将患者分为多个子集,并仅通过对推导子集进行交叉验证来优化模型。仅在验证集上计算模型的预测能力(平衡准确率、AUC、AUPCR、F1分数和MCC)。为确保结果的稳健性,重复优化10次。进行SHAP类型分析以确定个体变量的预测能力。

结果

该模型预测T3时的MMSE结果,平均AUC为0.643。模型可解释性分析表明,AD患者的整体认知状态进展与以下因素相关:空间记忆能力低(Corsi方块敲击测试)、言语情景长期记忆能力低(巴布科克故事回忆测试)和工作记忆能力低(斯特鲁普颜色测试)表现、高血压的存在、高胆固醇血症的不存在以及基线时IADL评分中的功能技能缺陷。

结论

这是第一项使用常规收集的临床数据预测AD患者认知轨迹的AI研究,同时还提供了导致这些轨迹的因素的可解释性。此外,我们的研究使用单个认知测试的结果作为特定认知功能的度量,相对于其他主要使用简短神经心理测试电池获得的综合分数的研究,能够对危险因素进行更细致的分析。这项工作的结果有助于对与疾病初始阶段相关的临床和认知变量进行预后解释,以实现个性化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8793/12149119/8f48709f7612/fnagi-17-1565006-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8793/12149119/5e9d999a85da/fnagi-17-1565006-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8793/12149119/8f48709f7612/fnagi-17-1565006-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8793/12149119/5e9d999a85da/fnagi-17-1565006-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8793/12149119/8f48709f7612/fnagi-17-1565006-g0002.jpg

相似文献

1
Neuropsychological and clinical variables associated with cognitive trajectories in patients with Alzheimer's disease.阿尔茨海默病患者认知轨迹相关的神经心理学和临床变量
Front Aging Neurosci. 2025 May 27;17:1565006. doi: 10.3389/fnagi.2025.1565006. eCollection 2025.
2
Longitudinal trajectories of cognitive, functional, and neuropsychiatric decline in Alzheimer's disease during COVID-19 lockdown in South Korea.韩国新冠疫情封锁期间阿尔茨海默病患者认知、功能及神经精神衰退的纵向轨迹
Sci Rep. 2025 Mar 8;15(1):8081. doi: 10.1038/s41598-025-92497-5.
3
Prediction of conversion to dementia using interpretable machine learning in patients with amnestic mild cognitive impairment.使用可解释机器学习预测遗忘型轻度认知障碍患者向痴呆症的转化。
Front Aging Neurosci. 2022 Aug 5;14:898940. doi: 10.3389/fnagi.2022.898940. eCollection 2022.
4
The Lawton Instrumental Activities Daily Living/Activities Daily Living Scales: A Sensitive Test to Alzheimer Disease in Community-Dwelling Elderly People?劳顿日常生活工具性活动/日常生活活动量表:对社区居住老年人的阿尔茨海默病是一种敏感测试吗?
J Geriatr Psychiatry Neurol. 2014 Jun;27(2):85-93. doi: 10.1177/0891988714522694. Epub 2014 Feb 26.
5
Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).用于检测轻度认知障碍(MCI)患者中阿尔茨海默病及其他痴呆症的简易精神状态检查表(MMSE)。
Cochrane Database Syst Rev. 2015 Mar 5;2015(3):CD010783. doi: 10.1002/14651858.CD010783.pub2.
6
Using Machine Learning to Predict Cognitive Decline in Older Adults From the Chinese Longitudinal Healthy Longevity Survey: Model Development and Validation Study.利用机器学习从中国老年健康长寿纵向调查预测老年人认知能力下降:模型开发与验证研究
JMIR Aging. 2025 Apr 30;8:e67437. doi: 10.2196/67437.
7
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.胆碱酯酶抑制剂在老年阿尔茨海默病患者中的有效性和安全性:一项“真实世界”研究。
Arch Gerontol Geriatr Suppl. 2004(9):297-307. doi: 10.1016/j.archger.2004.04.040.
8
9
Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).简易精神状态检查(MMSE)在轻度认知障碍(MCI)人群中用于早期发现痴呆。
Cochrane Database Syst Rev. 2021 Jul 27;7(7):CD010783. doi: 10.1002/14651858.CD010783.pub3.
10
Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration.遗忘型轻度认知障碍转化为阿尔茨海默病型痴呆与记忆衰退无关。
Int J Geriatr Psychiatry. 2007 Dec;22(12):1217-22. doi: 10.1002/gps.1816.

本文引用的文献

1
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.《痴呆症的预防、干预与照护:柳叶刀常设委员会2024年报告》
Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31.
2
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.基于生物标志物的神经认知障碍诊断的欧洲协会间推荐意见。
Lancet Neurol. 2024 Mar;23(3):302-312. doi: 10.1016/S1474-4422(23)00447-7.
3
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.
抗淀粉样蛋白单克隆抗体治疗阿尔茨海默病。
BioDrugs. 2024 Jan;38(1):5-22. doi: 10.1007/s40259-023-00633-2. Epub 2023 Nov 13.
4
The complex pathway between amyloid β and cognition: implications for therapy.淀粉样蛋白β与认知之间的复杂关系:对治疗的启示。
Lancet Neurol. 2023 Sep;22(9):847-857. doi: 10.1016/S1474-4422(23)00128-X. Epub 2023 Jul 13.
5
The Matthews correlation coefficient (MCC) should replace the ROC AUC as the standard metric for assessing binary classification.马修斯相关系数(MCC)应取代受试者工作特征曲线下面积(ROC AUC),作为评估二元分类的标准指标。
BioData Min. 2023 Feb 17;16(1):4. doi: 10.1186/s13040-023-00322-4.
6
Diabetes, Hypertension, and the Risk of Dementia.糖尿病、高血压与痴呆症风险。
J Alzheimers Dis. 2022;89(1):323-333. doi: 10.3233/JAD-220207.
7
Vascular Cognitive Impairment (VCI).血管性认知障碍(VCI)。
Neurotherapeutics. 2022 Jan;19(1):68-88. doi: 10.1007/s13311-021-01170-y. Epub 2021 Dec 22.
8
Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.预测阿尔茨海默病淀粉样蛋白阳性患者的进展和认知能力下降。
Alzheimers Res Ther. 2021 Sep 6;13(1):151. doi: 10.1186/s13195-021-00886-5.
9
Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review.利用临床数据进行阿尔茨海默病痴呆症进展建模的机器学习:系统文献综述
JAMIA Open. 2021 Aug 2;4(3):ooab052. doi: 10.1093/jamiaopen/ooab052. eCollection 2021 Jul.
10
Long-Term Increase in Cholesterol Is Associated With Better Cognitive Function: Evidence From a Longitudinal Study.胆固醇长期升高与更好的认知功能相关:一项纵向研究的证据。
Front Aging Neurosci. 2021 Jun 17;13:691423. doi: 10.3389/fnagi.2021.691423. eCollection 2021.